ResMed Inc. is a medical device company with a market cap of $37.4 billion, offering solutions for respiratory disorders. The company’s stock has fallen 12.7% from its 52-week high, underperforming the S&P 500. Despite this, ResMed posted strong Q1 2026 results, showing revenue growth and operational strength. Analysts remain moderately optimistic, with a mean price target of $291.31.

Read more at Yahoo Finance: Is ResMed Stock Underperforming the S&P 500?